Addex therapeutics reports 2024 half year and second quarter financial results and provides corporate update

Launched neurosterix with perceptive advisors to accelerate the development of m4pam for schizophrenia indivior selected gaba b pam drug candidate for development in substance use disorders addex selected independent gabab pam drug candidate for development in chronic cough ad hoc announcement pursuant to art. 53 lr geneva, switzerland, september 30, 2024 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended june 30, 2024, and provided a corporate update.
ADXN Ratings Summary
ADXN Quant Ranking